Ausgabe 4/2016
Inhalt (23 Artikel)
Unique features of trabectedin mechanism of action
Annette K. Larsen, Carlos M. Galmarini, Maurizio D’Incalci
Epigenetic alternations and cancer chemotherapy response
Jin-Feng Lv, Lei Hu, Wei Zhuo, Cong-Min Zhang, Hong-Hao Zhou, Lan Fan
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
Gareth J. Veal, Julie Errington, Jairam Sastry, Julia Chisholm, Penelope Brock, Daniel Morgenstern, Kathy Pritchard-Jones, Tanzina Chowdhury
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
Steven J. Cohen, Bert H. O’Neil, Jordan Berlin, Patricia Ames, Marti McKinley, Julie Horan, Patricia M. Catalano, Angela Davies, Colin D. Weekes, Lawrence Leichman
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
Yanli Li, Zandra Klippel, Xiaolong Shih, Hong Wang, Maureen Reiner, John H. Page
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
Dimitrios T. Trafalis, Constantinos Alifieris, George P. Stathopoulos, Nikolaos Sitaras
Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients
Seong-Jang Kim, Phillip J. Koo, Samuel Chang
Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
Anubha Gupta, Ziad Hussein, Raffit Hassan, Jason Wustner, Julia D. Maltzman, Bruce A. Wallin
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
Varun Goel, Eunju Hurh, Andrew Stein, Jerry Nedelman, Jocelyn Zhou, Ovidiu Chiparus, Pai-Hsi Huang, Sven Gogov, Dalila Sellami
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A
Ya-Tian Chen, Feng Zhu, Wei-Ren Lin, Rong-Biao Ying, You-Ping Yang, Ling-Hui Zeng
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
David Planchard, Kathryn H. Brown, Dong-Wan Kim, Sang-We Kim, Yuichiro Ohe, Enriqueta Felip, Philip Leese, Mireille Cantarini, Karthick Vishwanathan, Pasi A. Jänne, Malcolm Ranson, Paul A. Dickinson
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity
Charles Guenancia, Olivier Hachet, Mona Aboutabl, Na Li, Eve Rigal, Yves Cottin, Luc Rochette, Catherine Vergely
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
Kenji Tamura, Jun Hashimoto, Yuko Tanabe, Makoto Kodaira, Kan Yonemori, Takashi Seto, Fumihiko Hirai, Shuji Arita, Gouji Toyokawa, Lan Chen, Hiroshi Yamamoto, Toshio Kawata, Justin Lindemann, Taito Esaki
Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo
Bingfei Xu, Yu Wang, Jing Yang, Zhengfeng Zhang, Ying Zhang, Hansong Du
Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
Daniele Ouellet, Nastya Kassir, Joannellyn Chiu, Mohamad-Samer Mouksassi, Cathrine Leonowens, Donna Cox, Douglas J. DeMarini, Olivia Gardner, Wendy Crist, Kiran Patel
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
Russell Petty, Alan Anthoney, Jean-Philippe Metges, Maria Alsina, Anthony Gonçalves, Jennifer Brown, Clara Montagut, Katharina Gunzer, Gianluca Laus, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Patrick Bohan, Ramón Salazar
Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients
Srinivasu Poondru, Jorge Chaves, Geoffrey Yuen, Barbara Parker, Elizabeth Conklin, Margaret Singh, Masanori Nagata, Stanley Gill
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
Beverly Knight, Danielle Rassam, Shanmei Liao, Reginald Ewesuedo
Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis
Patrick Borentain, Sylvie Carmona, Sylvie Mathieu, Elisabeth Jouve, Assou El-Battari, René Gérolami
Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors
Maurizio Lucchesi, Milena Guidi, Carla Fonte, Silvia Farina, Patrizio Fiorini, Claudio Favre, Maurizio de Martino, Iacopo Sardi
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
Dong-Yeop Shin, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Jee Hyun Kong, Jeong-A Kim, Byung-Su Kim, Hyo Jung Kim, Jong-Ho Won, Sung-Kyu Park, Won Seog Kim
Oxytocin as a protective agent in cisplatin-induced ototoxicity
Zekiye Eda Bekmez Bilmez, Sedat Aydin, Arif Şanli, Niyazi Altintoprak, Mehmet Gökhan Demir, Banu Atalay Erdoğan, Ebru Kösemihal
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases
Siqing Fu, Kirk S. Culotta, Gerald S. Falchook, David S. Hong, Alan L. Myers, Yan-Ping Zhang, Aung Naing, Filip Janku, Ming-Mo Hou, Razelle Kurzrock